
Opinion|Videos|May 16, 2024
Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics
The expert panel explores the importance of communication and collaboration among care providers when patients with multiple myeloma who are receiving treatment with bispecific antibodies navigate transitions of care to and from various healthcare settings.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
2
CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program
3
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
4
Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review
5






















